Clinical Trial Update: Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy trial of Beclomethasone Dipropionate HFA 320 mcg for allergic rhinitis completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Beclomethasone Dipropionate HFA 320 mcg (Beclomethasone dipropionate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Rhinitis, Allergic, Perennial | Phase 3 | Status: COMPLETED | Results posted: 2012-05-23